

BioLight Announces Issuance of Japanese Patent for the IOptiMate™ Technology

TEL AVIV (June 1, 2015) - BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT; OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that the Japanese Patent Office has issued patent “DEVICE AND METHOD FOR LASER ASSISTED DEEP SCLERECTOMY”, related to the core of the IOptiMate™ Technology for a non-penetrating laser assisted filtration surgery technology for treating glaucoma.

The patent, which is owed by IOptima, one of BioLight’s subsidiaries, will be in effect at least until December 2029.

The patent joins the registration of patents in other territories worldwide.

The registration of the patent is subject to customary fee payment.